Skip to main content
. 2023 Oct 31;46:83–89. doi: 10.1016/j.jor.2023.10.033

Table 3.

Individual AAOS guidelines AGREE II domain scores organized in ascending order of average AGREE II score.

AAOS Guideline Title Scope and Purpose
Stakeholder Involvement
Rigor of Development
Clarity of Presentation
Applicability
Editorial Independence
Average AGREE II
Avg. AGREE II Score ±95% CI (Avg. %) Avg. AGREE II Score ±95% CI (Avg. %) Avg. AGREE II Score ±95% CI (Avg. %) Avg. AGREE II Score ±95% CI (Avg. %) Avg. AGREE II Score ±95% CI (Avg. %) Avg. AGREE II Score ±95% CI (Avg. %) Avg. AGREE II Score ±95% CI (Avg. %)
Prevention of Orthopaedic Implant Infection in Patients Undergoing Dental Procedures 5.30 ± 0.91 (82) 5.32 ± 1.24 (83) 5.31 ± 1.22 (84) 5.35 ± 1.12 (85) 2.32 ± 0.47 (41) 5.34 ± 1.10 (85) 5.36 ± 1.11 (85)
Acute Compartment Syndrome 5.15 ± 1.25 (80) 5.19 ± 0.93 (81) 5.20 ± 0.96 (82) 5.22 ± 0.97 (83) 2.48 ± 0.39 (45) 5.21 ± 0.98 (82) 5.20 ± 0.99 (82)
Management of Osteoarthritis of the Knee (Non-Arthroplasty) 5.89 ± 1.08 (95) 5.88 ± 1.03 (94) 5.86 ± 1.11 (93) 5.87 ± 1.09 (94) 2.94 ± 0.34 (54) 5.85 ± 1.05 (94) 5.84 ± 1.04 (93)
Use of Imaging Prior to Referral to a Musculoskeletal Oncologist 5.26 ± 1.21 (84) 5.23 ± 1.29 (82) 5.24 ± 1.13 (83) 5.27 ± 1.15 (84) 2.51 ± 0.45 (46) 5.28 ± 1.14 (84) 5.29 ± 1.13 (84)
Treatment of Pediatric Supracondylar Humerus Fractures 5.17 ± 0.88 (81) 5.18 ± 0.85 (81) 5.17 ± 0.89 (81) 5.18 ± 0.83 (81) 2.17 ± 0.38 (40) 5.19 ± 0.81 (82) 5.16 ± 0.82 (80)
Treatment of Metastatic Carcinoma and Myeloma of the Femur 5.21 ± 1.14 (83) 5.25 ± 1.02 (83) 5.28 ± 1.01 (84) 5.30 ± 1.03 (84) 2.41 ± 0.37 (43) 5.29 ± 1.02 (84) 5.28 ± 1.00 (83)
Clinical Practice Guideline for the Treatment of Clavicle Fractures 5.41 ± 0.97 (85) 5.42 ± 1.11 (85) 5.46 ± 1.15 (86) 5.44 ± 1.11 (86) 2.58 ± 0.35 (49) 5.45 ± 1.13 (86) 5.43 ± 1.14 (86)
Evaluation of Psychosocial Factors Influencing Recovery from Adult Orthopaedic Trauma 5.48 ± 1.09 (86) 5.47 ± 0.92 (86) 5.50 ± 0.94 (87) 5.49 ± 0.90 (87) 2.89 ± 0.33 (53) 5.48 ± 0.89 (87) 5.47 ± 0.87 (87)
Diagnosis and Treatment of Osteochondritis Dissecans 5.33 ± 0.94 (84) 5.34 ± 1.05 (85) 5.36 ± 1.06 (85) 5.38 ± 1.07 (86) 2.52 ± 0.36 (46) 5.37 ± 1.08 (85) 5.38 ± 1.09 (86)
Pharmacologic, Physical, and Cognitive Pain Alleviation for Musculoskeletal Extremity/Pelvis Surgery 5.22 ± 1.11 (83) 5.21 ± 0.97 (82) 5.23 ± 1.04 (83) 5.26 ± 1.06 (84) 2.46 ± 0.40 (44) 5.24 ± 1.04 (83) 5.25 ± 1.03 (83)
Diagnosis and Prevention of Periprosthetic Joint Infections 5.64 ± 0.96 (89) 5.62 ± 1.19 (89) 5.61 ± 1.12 (88) 5.63 ± 1.10 (88) 2.72 ± 0.31 (51) 5.62 ± 1.11 (88) 5.60 ± 1.12 (88)
Management of Distal Radius Fractures 5.28 ± 1.00 (84) 5.27 ± 0.90 (83) 5.29 ± 0.92 (84) 5.32 ± 0.94 (85) 2.35 ± 0.38 (42) 5.31 ± 0.95 (84) 5.33 ± 0.96 (85)
Treatment of Pediatric Diaphyseal Femur Fractures 5.50 ± 1.19 (87) 5.51 ± 1.13 (87) 5.53 ± 1.19 (88) 5.55 ± 1.18 (88) 2.67 ± 0.34 (50) 5.54 ± 1.15 (88) 5.53 ± 1.16 (88)
Management of Surgical Site Infections 5.53 ± 0.95 (88) 5.54 ± 0.99 (88) 5.52 ± 0.98 (88) 5.53 ± 0.89 (88) 2.62 ± 0.33 (49) 5.52 ± 0.87 (87) 5.50 ± 0.86 (87)
Management of Osteoarthritis of the Hip (update pending) 5.40 ± 1.02 (85) 5.37 ± 1.20 (85) 5.40 ± 1.16 (85) 5.42 ± 1.14 (86) 2.53 ± 0.39 (47) 5.41 ± 1.16 (86) 5.40 ± 1.15 (85)
Management of Glenohumeral Joint Osteoarthritis 5.11 ± 1.31 (80) 5.12 ± 1.28 (80) 5.13 ± 1.26 (80) 5.14 ± 1.24 (80) 2.19 ± 0.37 (40) 5.15 ± 1.22 (81) 5.13 ± 1.20 (80)
Limb Salvage or Early Amputation 5.70 ± 0.86 (91) 5.69 ± 0.88 (91) 5.71 ± 0.90 (92) 5.72 ± 0.88 (92) 2.92 ± 0.32 (53) 5.73 ± 0.84 (92) 5.74 ± 0.83 (92)
Carpal Tunnel Syndrome (update pending) 5.56 ± 1.05 (89) 5.57 ± 1.04 (88) 5.56 ± 1.06 (88) 5.59 ± 1.07 (89) 2.64 ± 0.34 (49) 5.58 ± 1.08 (89) 5.57 ± 1.09 (89)
Venous Thromboembolic Disease in Elective TKA and THA 5.60 ± 1.22 (90) 5.59 ± 1.10 (89) 5.58 ± 1.14 (89) 5.57 ± 1.12 (89) 2.56 ± 0.36 (48) 5.56 ± 1.13 (89) 5.55 ± 1.10 (88)
Detection and Nonoperative Management of Pediatric Developmental Dysplasia of the Hip in Infants Up to 6 Months of Age 5.08 ± 1.17 (79) 5.09 ± 1.15 (79) 5.10 ± 1.18 (80) 5.11 ± 1.16 (80) 2.16 ± 0.35 (39) 5.12 ± 1.17 (81) 5.14 ± 1.18 (80)
Management of Anterior Cruciate Ligament Injuries 5.75 ± 1.16 (92) 5.76 ± 1.07 (92) 5.77 ± 1.09 (93) 5.78 ± 1.05 (93) 2.87 ± 0.30 (52) 5.79 ± 1.03 (93) 5.80 ± 1.02 (93)
Management of Rotator Cuff Injuries 5.16 ± 1.03 (81) 5.17 ± 0.95 (81) 5.18 ± 0.91 (81) 5.19 ± 0.92 (82) 2.24 ± 0.39 (41) 5.20 ± 0.90 (82) 5.19 ± 0.88 (82)
Surgical Management of Osteoarthritis of the Knee 5.35 ± 0.99 (84) 5.36 ± 1.01 (84) 5.38 ± 1.03 (86) 5.37 ± 1.01 (85) 2.44 ± 0.37 (44) 5.39 ± 0.99 (86) 5.39 ± 0.98 (85)
Prevention of Surgical Site Infection After Major Extremity Trauma 5.20 ± 1.26 (82) 5.22 ± 1.16 (82) 5.21 ± 1.10 (82) 5.23 ± 1.08 (83) 2.50 ± 0.38 (45) 5.22 ± 1.09 (83) 5.23 ± 1.07 (82)
Anesthesia and Analgesia in Total Joint Arthroplasty (2021) 5.13 ± 1.15 (80) 5.14 ± 1.12 (80) 5.15 ± 1.20 (80) 5.16 ± 1.18 (81) 2.27 ± 0.36 (42) 5.17 ± 1.19 (82) 5.18 ± 1.17 (81)
Tranexamic Acid in Total Joint Arthroplasty 5.19 ± 1.30 (82) 5.20 ± 1.14 (82) 5.19 ± 1.05 (81) 5.21 ± 1.04 (82) 2.42 ± 0.35 (43) 5.23 ± 1.06 (83) 5.24 ± 1.05 (83)
Anesthesia and Analgesia in Total Joint Arthroplasty (2020) 5.67 ± 0.89 (90) 5.65 ± 0.91 (90) 5.66 ± 0.87 (90) 5.68 ± 0.86 (91) 2.76 ± 0.31 (51) 5.67 ± 0.85 (90) 5.66 ± 0.84 (90)
Management of Hip Fractures in Older Adults 5.58 ± 1.11 (89) 5.55 ± 1.08 (88) 5.54 ± 1.02 (87) 5.56 ± 1.00 (88) 2.60 ± 0.33 (48) 5.55 ± 1.01 (87) 5.54 ± 0.99 (88)

AAOS = American Academy of Orthopaedic Surgeons ⎟ TKA = Total Knee Arthroplasty ⎟ THA = Total Hip Arthroplasty.